US5490984A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of injectable biomaterials for the repair and augmentation of the anal sphincters
Assignee: JSF Consultants Ltd
•
Filing: 1995-05-18
•
Granted: 1996-02-13
•
Expires: 2015-05-18
Abstract
Abstract This invention discloses methods of repairing structurally defective or inadequately functioning muscles of the anal sphincter and methods of improving the competency of incompetent anal sphincters by administering an effective amount of an injectable biomaterial into the defect or into the anal sinuses, Preferred biomaterials to be used in this invention are collagen formulations.
Inventors
- 👤 Jeffrey S. Freed
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:08
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/39; A61F; A61F2/00; A61F2/0004; A61P; A61P1/00
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
59 words
A method of inducing wound healing of a structurally defective anal sphincter comprising administering an effective amount of an injectable biomaterial, capable of persisting at the injection site for at least three months containing a therapeutically effective amount of one or more wound healing agents, into the defect, sufficient to induce wound healing of a structurally defective anal sphincter.
Claim 2
Independent Claim
59 words
A method of inducing wound healing of a structurally defective anal sphincter comprising administering an effective amount of an injectable biomaterial, capable of persisting at the injection site for at least three months containing a therapeutically effective amount of one or more wound healing agents, into the defect, sufficient to induce wound healing of a structurally defective anal sphincter.
Claim 3
Dependent Claim
16 words
The method of claim 1 wherein said injectable biomaterial is atelopeptide fibrillar, crosslinked or non-crosslinked collagen.
Claim 4
Dependent Claim
21 words
The method of claim 1 wherein said injectable biomaterial is an aqueous suspension of a biopolymer with a biocompatible fluid lubricant.
Claim 5
Dependent Claim
36 words
The method of claim 3 wherein said biopolymer is selected from the group consisting of: atelopeptide fibrillar, crosslinked collagen, non-crosslinked collagen, gelatin beads, polytetrafluoroethylene beads, silicone rubber beads, hydrogel beads, silicon carbide beads, and glass beads.
Claim 6
Dependent Claim
41 words
The method of claim 3 wherein said biocompatible fluid lubricant is selected from the group consisting of: hyaluronic acid, dextran sulfate, dextran, succinylated non-crosslinked collagen, methylated non-crosslinked collagen, glycogen, glycerol, dextrose, maltose, triglycerides of fatty acids, egg yolk phospholipids, and heparin.
Claim 7
Dependent Claim
14 words
The method of claim 1 wherein said injectable biomaterial is a second nucleation collagen.
Claim 8
Dependent Claim
15 words
The method of claim 2 wherein said collagen is conjugated to a chemically activated polymer.
Claim 9
Dependent Claim
13 words
The method of claim 7 wherein said chemically activated polymer is polyethylene glycol.
Claim 10
Dependent Claim
15 words
The method of claim 2 wherein said collagen is crosslinked with a bifunctional activated polymer.
Claim 11
Dependent Claim
16 words
The method of claim 9 wherein said collagen and said bifunctional activated polymer crosslink in situ.
Claim 12
Dependent Claim
13 words
The method of claim 9 wherein said bifunctional activated polymer is polyethylene glycol.
Claim 13
Dependent Claim
15 words
The method of claim 1 wherein said biomaterial further comprises a ceramic and/or mineral material.
Claim 14
Dependent Claim
20 words
The method of claim 12 wherein said ceramic material comprises ceramic particles in the size range of about 50-250 microns.
Claim 15
Dependent Claim
40 words
The method of claim 1 wherein said wound healing agent is selected from the group consisting of: fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), epidermal growth factors (EGFs), connective tissue activating peptides (CTAPs), and transforming growth factors (TGFs).
Claim 16
Dependent Claim
20 words
The method of claim 1 wherein said biomaterial further comprises a therapeutically effect amount of an antimicrobial additive and/or antibiotic.
References Cited (Backward Citations)
US2696456A
Cited
US3197369A
Cited
US3650275A
Cited
US3749100A
Cited
US3952726A
Cited
US3949073A
Cited
US4209009A
Cited
US4424208A
Cited
US4582640A
Cited
US4401107A
Cited
US4686985A
Cited
US4904256A
Cited
US4760131A
Cited
US4803075A
Cited
US4781176A
Cited
US4969902A
Cited
US4950483A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-02-12 | 1999-08-14 | 2000-02-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-02-12 | 2003-08-14 | 2004-02-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-02-12 | 2007-08-14 | 2008-02-13 | $7700.00 | Window Closed / Lapsed |